ARISTOSPAN

Clinical safety rating: caution

Comprehensive clinical and safety monograph for ARISTOSPAN (ARISTOSPAN).

How it works

Corticosteroid that binds to glucocorticoid receptors, modulating gene expression and suppressing inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.

What the body does with it

Metabolism	Hepatic, primarily via CYP3A4; triamcinolone acetonide is metabolized to inactive metabolites.
Excretion	Primarily hepatic metabolism; renal excretion of inactive metabolites (<5% unchanged); minimal biliary/fecal excretion.
Half-life	Triamcinolone hexacetonide: terminal half-life approximately 2-3 weeks (88-144 hours) due to slow release from depot site; clinical effects persist for weeks to months.
Protein binding	Approximately 68% bound, primarily to corticosteroid-binding globulin (CBG) and albumin.
Volume of Distribution	Approximately 1.4 L/kg (triamcinolone base); reflects extensive tissue distribution and slow release from injection site.
Bioavailability	Intramuscular: near 100% (complete absorption); oral: not applicable (not administered orally); intra-articular: local availability near 100% with minimal systemic absorption.
Onset of Action	Intra-articular: 3-7 days for anti-inflammatory effect; intramuscular: 24-72 hours.
Duration of Action	Intra-articular: 2-5 weeks (single injection); intramuscular: 2-4 weeks; clinical effect may last up to 6-8 weeks in some patients.

Classification & Brands

Dosing & administration

Triamcinolone hexacetonide (Aristospan) is administered intra-articularly or intralesionally. For intra-articular use in adults, typical dose is 2–20 mg (0.5–1 mL of 20 mg/mL suspension) depending on joint size. For intralesional use, 2–3 mg per injection site, with total dose not exceeding 0.5 mg/kg per day.

Dosage form	INJECTABLE
Renal impairment	No specific dose adjustment required for renal impairment; however, caution in severe impairment due to potential corticosteroid side effects (e.g., fluid retention). No GFR-based guidelines available.
Liver impairment	No specific dose adjustments for Child-Pugh classification; use caution in severe hepatic impairment due to increased risk of corticosteroid systemic effects.
Pediatric use	Not approved for pediatric use. However, off-label dosing: intra-articular 0.5–1 mg/kg (max 20 mg) for large joints; intralesional 0.1–0.5 mg per injection site. Use lowest effective dose and shortest duration.
Geriatric use	Elderly patients may have increased susceptibility to corticosteroid adverse effects (e.g., osteoporosis, hypertension, glucose intolerance). Use lowest effective dose and monitor closely. No specific dose adjustment recommended.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for ARISTOSPAN (ARISTOSPAN).

Breastfeeding	Enters breast milk; M/P ratio unknown. Low doses unlikely to cause adverse effects; high doses may suppress infant adrenal function. Use caution, consider infant monitoring.
Teratogenic Risk	First trimester: Increased risk of cleft palate (odds ratio 3-5), intrauterine growth restriction. Second/third trimester: Fetal adrenal suppression, electrolyte abnormalities, preterm labor reduction, oligohydramnios with prolonged use.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Intrathecal administration is contraindicated due to risk of serious neurologic events.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to triamcinolone or any component","Systemic fungal infection","Intrathecal administration (black box warning)","Administration of live or live-attenuated vaccines"]

Clinical Precautions

Precautions	["Cardiovascular: Increased risk of myocardial infarction and stroke with prolonged use.","Endocrine: Adrenal suppression with prolonged therapy; avoid abrupt withdrawal.","Immunosuppression: Increased susceptibility to infections; avoid live vaccines.","Ophthalmic: Cataracts and glaucoma with long-term use."]
Food/Dietary	Avoid grapefruit and grapefruit juice as they may increase triamcinolone levels. Limit sodium intake to reduce fluid retention and hypertension. Increase potassium-rich foods (bananas, oranges) if hypokalemia occurs. Alcohol may increase gastrointestinal side effects.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

ARISTOSPAN

Clinical safety rating: caution

Comprehensive clinical and safety monograph for ARISTOSPAN (ARISTOSPAN).

How it works

Corticosteroid that binds to glucocorticoid receptors, modulating gene expression and suppressing inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.

What the body does with it

Metabolism	Hepatic, primarily via CYP3A4; triamcinolone acetonide is metabolized to inactive metabolites.
Excretion	Primarily hepatic metabolism; renal excretion of inactive metabolites (<5% unchanged); minimal biliary/fecal excretion.
Half-life	Triamcinolone hexacetonide: terminal half-life approximately 2-3 weeks (88-144 hours) due to slow release from depot site; clinical effects persist for weeks to months.
Protein binding	Approximately 68% bound, primarily to corticosteroid-binding globulin (CBG) and albumin.
Volume of Distribution	Approximately 1.4 L/kg (triamcinolone base); reflects extensive tissue distribution and slow release from injection site.
Bioavailability	Intramuscular: near 100% (complete absorption); oral: not applicable (not administered orally); intra-articular: local availability near 100% with minimal systemic absorption.
Onset of Action	Intra-articular: 3-7 days for anti-inflammatory effect; intramuscular: 24-72 hours.
Duration of Action	Intra-articular: 2-5 weeks (single injection); intramuscular: 2-4 weeks; clinical effect may last up to 6-8 weeks in some patients.

Classification & Brands

Dosing & administration

Dosage form	INJECTABLE
Renal impairment	No specific dose adjustment required for renal impairment; however, caution in severe impairment due to potential corticosteroid side effects (e.g., fluid retention). No GFR-based guidelines available.
Liver impairment	No specific dose adjustments for Child-Pugh classification; use caution in severe hepatic impairment due to increased risk of corticosteroid systemic effects.
Pediatric use	Not approved for pediatric use. However, off-label dosing: intra-articular 0.5–1 mg/kg (max 20 mg) for large joints; intralesional 0.1–0.5 mg per injection site. Use lowest effective dose and shortest duration.
Geriatric use	Elderly patients may have increased susceptibility to corticosteroid adverse effects (e.g., osteoporosis, hypertension, glucose intolerance). Use lowest effective dose and monitor closely. No specific dose adjustment recommended.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for ARISTOSPAN (ARISTOSPAN).

Breastfeeding	Enters breast milk; M/P ratio unknown. Low doses unlikely to cause adverse effects; high doses may suppress infant adrenal function. Use caution, consider infant monitoring.
Teratogenic Risk	First trimester: Increased risk of cleft palate (odds ratio 3-5), intrauterine growth restriction. Second/third trimester: Fetal adrenal suppression, electrolyte abnormalities, preterm labor reduction, oligohydramnios with prolonged use.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Intrathecal administration is contraindicated due to risk of serious neurologic events.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to triamcinolone or any component","Systemic fungal infection","Intrathecal administration (black box warning)","Administration of live or live-attenuated vaccines"]

Clinical Precautions

Precautions	["Cardiovascular: Increased risk of myocardial infarction and stroke with prolonged use.","Endocrine: Adrenal suppression with prolonged therapy; avoid abrupt withdrawal.","Immunosuppression: Increased susceptibility to infections; avoid live vaccines.","Ophthalmic: Cataracts and glaucoma with long-term use."]
Food/Dietary	Avoid grapefruit and grapefruit juice as they may increase triamcinolone levels. Limit sodium intake to reduce fluid retention and hypertension. Increase potassium-rich foods (bananas, oranges) if hypokalemia occurs. Alcohol may increase gastrointestinal side effects.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

Clinical Pearls	ARISTOSPAN (triamcinolone acetonide injectable suspension) is a long-acting glucocorticoid; use a 25- to 27-gauge needle for intralesional injection to minimize tissue trauma. Avoid intra-articular injection in unstable joints. Do not inject directly into tendons. Monitor for Cushing's syndrome with prolonged use. Taper dose when discontinuing after long-term therapy.
Patient Advice	Do not stop taking this medicine suddenly without consulting your doctor. · Report any signs of infection (fever, sore throat) or unusual bruising/bleeding. · Avoid live vaccines while on this medication. · Inform all healthcare providers that you are taking a corticosteroid. · May cause increased appetite, weight gain, and fluid retention.